Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381898 | 0.84 | CDK1 (0.43) | CDK1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL14375140 | 0.80 | CDK1 (0.57) | CDK1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL380378 | 0.77 | CDK1 (0.50) | CDK1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL12417531 | 0.75 | CDK1 (0.58) | CDK1ADORA2AADORA2BADORA1 | |
| SCHEMBL15756436 | 0.74 | ADORA2A (0.53) | CDK1ADORA2AADORA3ADORA1 | |
| SCHEMBL7893176 | 0.73 | ADORA2A (0.85) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22349412 | 0.71 | ADORA2A (0.63) | CDK1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL129640 | 0.70 | CDK1 (0.64) | CDK1ADORA2AADORA2BADORA1 | |
| SCHEMBL381174 | 0.69 | ADORA2A (0.56) | CDK1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL8008266 | 0.69 | CDK1 (1.00) | CDK1ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2016-01-07 | — | — | US | disclosed |
| US-9133197-B2 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| EP-2408775-B1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2015-06-17 | — | — | EP | disclosed |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ALFASIGMA S.P.A. (IT) | 2012-03-01 | — | — | US | disclosed |
| EP-2408775-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106145-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | CDK1 720/4885ADORA2A 1/4885ADORA2B 4/4885 |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | CDK1 720/4885ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.